Skip to content

Change in AP at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$409M+581%
Amgen logo
AmgenAMGN
$571M+14.9%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$7.97M-599%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$6.28M+65.8%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.67M-3.1%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$2.33M-13.0%

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s change in AP?
Climb Bio, Inc. (CLYM) reported change in AP of -$1.41M in Q1 2026.
How has Climb Bio, Inc.'s change in AP changed year-over-year?
Climb Bio, Inc.'s change in AP decreased by 2056.9% year-over-year, from $72K to -$1.41M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.